KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Repurchased
Ratios

Emergent BioSolutions (EBS) Amortization - Deferred Charges: 2015-2017

Historic Amortization - Deferred Charges for Emergent BioSolutions (EBS) over the last 2 years, with Dec 2017 value amounting to $95,000.

  • Emergent BioSolutions' Amortization - Deferred Charges fell 55.19% to $95,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $680,000, marking a year-over-year decrease of 15.74%. This contributed to the annual value of $681,000 for FY2017, which is 12.80% down from last year.
  • Per Emergent BioSolutions' latest filing, its Amortization - Deferred Charges stood at $95,000 for Q4 2017, which was down 51.28% from $195,000 recorded in Q3 2017.
  • Emergent BioSolutions' Amortization - Deferred Charges' 5-year high stood at $215,000 during Q3 2015, with a 5-year trough of $95,000 in Q4 2017.
  • Over the past 3 years, Emergent BioSolutions' median Amortization - Deferred Charges value was $195,000 (recorded in 2017), while the average stood at $189,111.
  • As far as peak fluctuations go, Emergent BioSolutions' Amortization - Deferred Charges increased by 7.61% in 2016, and later plummeted by 55.19% in 2017.
  • Over the past 3 years, Emergent BioSolutions' Amortization - Deferred Charges (Quarterly) stood at $197,000 in 2015, then climbed by 7.61% to $212,000 in 2016, then slumped by 55.19% to $95,000 in 2017.
  • Its Amortization - Deferred Charges stands at $95,000 for Q4 2017, versus $195,000 for Q3 2017 and $195,000 for Q2 2017.